Strategic License Agreement - Narrative (Details) - USD ($)			1 Months Ended		12 Months Ended
	Jul. 27, 2023	Mar. 21, 2021	Jul. 31, 2021	Jun. 30, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognized					$ 886,000	$ 2,329,000	$ 18,739,000
Deferred revenue					0	2,696,000
Deferred revenue, current					0	517,000
Contract assets					0	0
Proceeds from sale of intangible assets					15,000,000	0	0
Gain on sale of in-process research and development asset					16,449,000	0	0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Global Rights To Pegzilarginase
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Proceeds from sale of intangible assets	$ 15,000,000.0
Contingent consideration	100,000,000.0
Carrying value of assets	0
Gain on sale of in-process research and development asset	16,400,000
Contingent reimbursement of pre-paid manufacturing costs	1,800,000
Derecognition of nonfinancial assets and liabilities	$ 400,000
Immedica Pharma AB
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Reimbursement			$ 3,000,000.0
Non refundable payment received		$ 21,500,000
Percentage of payment for cost incurred in trial		50.00%
Maximum amount of costs to reimburse		$ 1,800,000
Additional upfront payment to be received		$ 120,800,000
Milestone payments exchange rate		1.07
Rate of revenue share		25.00%
Upfront payment		$ 21,500,000
Estimated amount incurred			3,600,000
Related party transaction amount			25,100,000
Allocation for stand-alone selling prices			12,000,000.0
Deferred revenue						2,700,000
Deferred revenue, current						500,000
Immedica Pharma AB | PEACE Trial and BLA Package
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Allocated amount of modified transaction price			9,600,000
Revenue recognized					$ 900,000	$ 2,300,000	6,700,000
Immedica Pharma AB | PIP Trial
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Allocated amount of modified transaction price			$ 3,500,000
Immedica Pharma AB | License Agreements
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue recognized				$ 12,000,000.0			$ 12,000,000.0